SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999, to receive the free SmallCapReview newsletter and be entered to win a Free iPod Touch visit http://www.smallcapreview.com.
Antigenics, Inc. (Nasdaq: AGEN) $0.96. Today announced the expansion of a phase 2 clinical study of HSPPC-96 (Oncophage(R) vaccine; vitespen), Antigenics' personalized therapeutic cancer vaccine, in patients with newly diagnosed glioma.
"Early results from this trial in the newly diagnosed setting are very encouraging, and we have seen no treatment-related toxicities," said Andrew T. Parsa, MD, PhD, associate professor in the Department of Neurological Surgery at the University of California, San Francisco and lead investigator in the trial now being expanded. "HSPPC-96 is part of an emerging frontier in personalized medicine for the treatment of cancer. Our data has shown that the vaccine triggers an immune response against the patient's cancer."
What They Do: Antigenics is a biotechnology company working to develop treatments for cancers and infectious diseases.
IMAX Corporation (Nasdaq: IMAX) $17.99. Today announced the launch of its new nXos Calibrator, a patent-pending technology designed to tune and automatically monitor IMAX audio systems. The new technology applies the equivalent of thousands of bands of equalization to perform a highly detailed tuning of the IMAX audio system. IMAX nXos Calibrator is designed to significantly exceed the capability of manual equalization processes.
IMAX's audio systems feature proprietary loudspeaker technology and uncompressed digital sound, with much greater dynamic range than conventional systems. The system is designed to provide a more immersive audio environment. The IMAX nXos Calibrator works to ensure that the audience is provided an optimum audio experience in the IMAX(R) theatre.
What They Do: IMAX Corporation is one of the world's leading entertainment technology companies, specializing in immersive motion picture technologies.
TeleCommunication Systems (Nasdaq: TSYS) $5.36. Today announced that it has received an additional $4.1 million in funding from the U.S. Army for equipment and maintenance of Secret Internet Protocol Router (SIPR) and Non-secure Internet Protocol Router (NIPR) Access Point (SNAP) Very Small Aperture Terminal (VSAT) Satellite Systems. These awards are exercised options on existing Delivery Orders issued by the U.S. Army Communications-Electronics Life Cycle Management Command (CECOM LCMC).
This additional increment of SNAP funding will provide equipment and support of TCS' highly reliable SwiftLink deployable communications products. The U.S. Army Project Manager for the Warfighter Information Network-Tactical (PM WIN-T) Commercial Satellite Terminal Program (CSTP) is funding these procurements through the Army's $5 billion World-Wide Satellite Systems (WWSS) contract vehicle. Under the SNAP program customers can exercise options and add funding through August 2011 for delivery per the term of the discrete order. The SNAP program includes options for approximately 1,500 terminals and supporting equipment to be deployed in various sizes and configurations, along with up to 30 field support positions. Under the WWSS procurement vehicle, customers may place orders through August 2011 for delivery up to a year thereafter.
What They Do: TeleCommunication Systems is a world leader in highly reliable and secure mobile communication technology.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com. To follow us on Twitter visit http://twitter.com/SmallCapReview.
